 |
|
|
Table 2. BFM Relapse Risk Group Assignment for Precursor B-cell ALLa
|
|
Extramedullary Relapse
|
Combined Bone Marrow and Extramedullary Relapse
|
Marrow Relapse
|
|
aAdapted from Roy et al. [14] and Borgmann et al.[22]
|
|
Very Early Relapse (<18 months from diagnosis)
|
Intermediate |
High |
High |
|
Early Relapse (>18 months from diagnosis and <6 months from completion of therapy)
|
Intermediate |
Intermediate |
High |
|
Late Relapse (>6 months from completion of therapy)
|
Standard |
Intermediate |
Intermediate |
References
-
Roy A, Cargill A, Love S, et al.: Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol 130 (1): 67-75, 2005.
[PUBMED Abstract]
-
Borgmann A, von Stackelberg A, Hartmann R, et al.: Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 101 (10): 3835-9, 2003.
[PUBMED Abstract]
|
|
|
